XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 26, 2025
Oct. 27, 2024
Oct. 26, 2025
Oct. 27, 2024
Jan. 26, 2025
Cash flows from operating activities:          
Net loss $ (2,862) $ (7,586) $ (10,581) $ (201,040)  
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization     30,633 33,211  
Amortization of right-of-use assets     4,094 4,542  
Investment impairments and credit loss reserves, net 0 0 0 1,109  
Goodwill impairment 0 0 41,991 0  
Accretion of deferred financing costs     3,697 6,814  
Write-off of deferred financing costs 1,872 0 2,388 5,497  
Loss on extinguishment of debt     0 143,467  
Induced conversion expense 21,188 0 21,188 0  
Interest rate swap termination     (1,145) 0  
Deferred income taxes     7,783 (944)  
Share-based compensation     41,270 50,777  
Loss on disposition of business operations and assets     41 124  
Equity method income (16) 12 (1,000) (38)  
Gain from sale of investments     0 (277)  
Corporate-owned life insurance, net     2,209 2,722  
Changes in assets and liabilities:          
Accounts receivable, net     (2,099) (8,142)  
Inventories     (22,077) (18,446)  
Other assets     (5,548) 597  
Accounts payable     15,641 18,911  
Accrued liabilities     (5,400) (8,813)  
Other liabilities     (3,404) (5,580)  
Net cash provided by operating activities     119,681 24,491  
Cash flows from investing activities:          
Proceeds from sales of property, plant and equipment     3 73  
Purchase of property, plant and equipment     (7,353) (5,228)  
Proceeds from sale of investments     1,936 2,650  
Purchase of investments     0 (434)  
Purchase of intangibles     (5,414) (5,948)  
Proceeds from corporate-owned life insurance     0 4,802  
Premiums paid for corporate-owned life insurance     (3,428) 0  
Net cash used in investing activities     (14,256) (4,085)  
Cash flows from financing activities:          
Payments of revolving line of credit     0 (5,000)  
Payments of term loans     (181,212) 0  
Proceeds from convertible senior notes     402,500 0  
Payments of convertible senior notes     (280,950) 0  
Purchase of capped calls     (31,395) 0  
Repurchase of warrants     (217,761) 0  
Proceeds from unwind of convertible note hedge     242,251 0  
Proceeds from interest rate swap termination     295 0  
Deferred financing costs     (10,626) (824)  
Payments for employee share-based compensation payroll taxes     (18,744) (7,297)  
Proceeds from exercise of stock options     1,538 1,248  
Distributions to noncontrolling interest     0 (184)  
Net cash used in financing activities     (94,104) (12,057)  
Effect of foreign exchange rate changes on cash and cash equivalents     1,606 (430)  
Net increase in cash and cash equivalents     12,927 7,919  
Cash and cash equivalents at beginning of period     151,743 128,585 $ 128,585
Cash and cash equivalents at end of period $ 164,670 $ 136,504 164,670 136,504 $ 151,743
Supplemental disclosure of cash flow information:          
Interest paid     15,136 60,563  
Income taxes paid     5,994 6,881  
Non-cash investing and financing activities:          
Accounts payable related to capital expenditures     473 511  
Accrued deferred financing costs     1,026 0  
Accrued purchases of intangibles     2,195 2,950  
Debt extinguished in exchange for common stock     0 188,050  
Write-off of deferred financing costs pursuant to induced conversion     $ 4,598 $ 0